While patients beyond Milan criteria but with AFP models of up to 2 points were recently shown to be at an increased, yet still acceptable, risk of tumor recurrence, this does not seem to apply to patients with intrahepatic dissemination [27]. The gene discussed is AFP; the disease is neoplasm.